新型降心率药物伊伐布雷定安全性的系统评价

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (4): 251-254.

• 安全性评价与合理用药 • 上一篇下一篇

新型降心率药物伊伐布雷定安全性的系统评价

姜欢, 王瑶, 闫虹, 姜颖^*

吉林大学第二医院产科三疗区,吉林长春130041

收稿日期:2018-05-29 修回日期:2018-05-29 出版日期:2018-04-20 发布日期:2018-05-29
通讯作者: 姜颖,女,主管护师,护理学。E-mail: 20834616@163.com
作者简介:姜欢,女,护士,护理学。

Systematic Review of the Safety of the Heart Rate Lowering Drug Ivabradine

JIANG Huan, WANG Yao, YAN Hong, JIANG Ying^*

The Third Treatment Area of Obstetrical Department in the Second Hospital of Jilin University, Jilin Changchun 130041, China

Received:2018-05-29 Revised:2018-05-29 Online:2018-04-20 Published:2018-05-29

摘要/Abstract

摘要： 目的系统评价伊伐布雷定降心率治疗的安全性。方法检索Pubmed、中国知网等数据库中关于伊伐布雷定降心率治疗的随机对照研究,时间截止2017年10月,根据纳入标准和排除标准对文献进行筛选,使用Stata 14.1及Rev Man 5.3软件进行Meta分析。结果共纳入10篇随机对照研究。Meta分析结果表明,伊伐布雷定相比对照药显著增加心动过缓发生率（RR=4.16, 95% CI: 2.61-6.63, I²=92%, P <0.00001）及光幻视发生率(RR=5.07, 95% CI: 3.31-7.77, I²=68%,P <0.00001)。结论伊伐布雷定所致心动过缓、光幻视风险较高,因此临床使用中需充分权衡利弊。

关键词: 伊伐布雷定, 系统评价, Meta分析, 安全性

Abstract: Objective To evaluate the safety of ivabradine in decreasing heart rate. Methods The randomized controlled trials of ivabradine in decreasing heart rate, which had been published from the time of library foundation to October, 2017 were collected from Pubmed, CNKI database according to the including criteria. The results of studies were analyzed through Stata 14.1 software and Rev Man 5.3 software. Results Ten randomized controlled trials were included. Meta-analysis showed that there was significant difference between ivabradine and controls in bradycardia (RR=4.16, 95% CI: 2.61-6.63, I²=92%, P<0.00001) and phosphenes (RR=5.07, 95% CI: 3.31-7.77, I²=68%, P <0.00001). Conclusion Meta-analysis proved that ivabradine was associated with a significant increase in the risk of bradycardia and phosphenes. Therefore, clinicians need to take these risks into account in treatment.

Key words: ivabradine, systematic review, meta-analysis, safety

中图分类号:

姜欢, 王瑶, 闫虹, 姜颖. 新型降心率药物伊伐布雷定安全性的系统评价[J]. 中国药物警戒, 2018, 15(4): 251-254.

JIANG Huan, WANG Yao, YAN Hong, JIANG Ying. Systematic Review of the Safety of the Heart Rate Lowering Drug Ivabradine[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 251-254.

参考文献

[1] DiFrancesco D.Funny channels in the control of cardiac rhythm and mode of action of selective blockers[J].PHARMACOL RES, 2006, 53(5): 399-406.
[2] Tardif J C, Ford I, Tendera M,et al.Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina[J].EUR HEART J, 2005, 26(23): 2529-2536.
[3] Ruzyllo W, Tendera M, Ford I,et al.Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial[J].DRUGS, 2007, 67(3): 393-405.
[4] Amosova E, Andrejev E, Zaderey I,et al.Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina[J].Cardiovasc Drugs Ther, 2011, 25(6): 531-537.
[5] Swedberg K, Komajda M, Bohm M,et al.Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J].LANCET, 2010, 376(9744): 875-885.
[6] US. Food and Drug Administration. CORLANOR (ivabradine) safely and effectively[EB/OL]. (2015-04-15)[2017-10-15]. https://www.fda.gov/Drugs/.
[7] . Martin R I, Pogoryelova O, Koref MS,et al.Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials[J].HEART, 2014, 100(19): 1506-1510.
[8] The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0[M/OL]. (2011-03-01)[2017-10-15]. http://handbook.cochrane.org/.
[9] Fox K, Ford I, Steg P G,et al.Ivabradine in stable coronary artery disease without clinical heart failure[J].N Engl J Med, 2014, 371(12): 1091-1099.
[10] Celik O, Atasoy M M, Erturk M,et al.Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy[J].ACTA RADIOL, 2014, 55(6): 676-681.
[11] Pichler P, Pichler-Cetin E, Vertesich M,et al.Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography[J].AM J CARDIOL, 2012, 109(2): 169-173.
[12] Fasullo S, Cannizzaro S, Maringhini G,et al.Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings[J].J CARD FAIL, 2009, 15(10): 856-863.
[13] Tardif J C, Ponikowski P, Kahan T.Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial[J].EUR HEART J, 2009, 30(5): 540-548.
[14] Fox K, Ford I, Steg P G,et al.Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial[J].LANCET, 2008, 372(9641): 807-816.
[15] Borer J S, Fox K, Jaillon P,et al.Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial[J].CIRCULATION, 2003, 107(6): 817-823.
[16] McMurray J J, Adamopoulos S, Anker S D,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J].EUR J HEART FAIL, 2012, 14(8): 803-869.
[17] Montalescot G, Sechtem U, Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J].EUR HEART J, 2013, 34(38): 2949-3003.
[18] Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines on the diagnosis and treatment of Heart Failure[J]. Chinese Journal of Cardiology 2014,42(2): 98-122.
[19] Yaniv Y, Sirenko S, Ziman B D,et al.New evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca(2)(+) cycling[J].J MOL CELL CARDIOL, 2013, 62: 80-89.
[20] European Medicines Agency. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)[EB/OL].(2014-11-10)[2017-10-11]. http://www.ema.europa.eu/ema/.
[21] Scicchitano P, Cortese F, Ricci G,et al.Ivabradine, coronary artery disease, and heart failure: beyond rhythm control[J].Drug Des Devel Ther, 2014, 8: 689-700.

新型降心率药物伊伐布雷定安全性的系统评价

Systematic Review of the Safety of the Heart Rate Lowering Drug Ivabradine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[2]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[3]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[4]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[5]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[6]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[7]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[8]	刘倩, 胡晶, 李博, 杨小静. 荆花胃康胶丸联合四联疗法治疗幽门螺旋杆菌相关性胃炎的系统评价及Meta分析[J]. 中国药物警戒, 2023, 20(9): 1039-1045.
[9]	于洪礼, 于冬梅, 肖爱丽, 朱兰, 宋海波. 清开灵口服制剂安全性风险分析[J]. 中国药物警戒, 2023, 20(9): 1046-1048.
[10]	李婧, 徐烨, 刘冉佳, 潘晨, 崔向丽. 新型冠状病毒感染患者使用托珠单抗后发生不良反应的病例分析[J]. 中国药物警戒, 2023, 20(9): 1049-1053.
[11]	地力乎马·地力木拉提, 石伟, 王伽伯, 高源. 基于毒/效记载演变探讨补骨脂的安全应用研究进展[J]. 中国药物警戒, 2023, 20(8): 939-945.
[12]	李亚梅, 水荣. 托法替尼治疗幼年特发性关节炎研究进展[J]. 中国药物警戒, 2023, 20(8): 956-960.
[13]	王荣, 刘自群, 王娜娜, 谭雄, 张怡心, 杨宽, 秦蓓. 脯氨酸丹参素冰片酯对小鼠急性毒性研究[J]. 中国药物警戒, 2023, 20(7): 754-757.
[14]	左泽平, 田颖颖, 徐意, 姜克武, 杨硕, 杨海润, 张志聪, 曹欣垚, 吴笑如, 王志斌. 金匮肾气丸临床前安全性评价研究[J]. 中国药物警戒, 2023, 20(7): 775-782.
[15]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.